新瑞鹏宠物医疗，在美国递交招股书，拟纳斯达克IPO上市，摩根士丹利、瑞信、中金、瑞银联席承销

2023年1月23日，来自广东深圳的新瑞鹏宠物医疗集团的控股公司New Ruipeng Pet Group Inc.（以下简称“新瑞鹏”）在美国证监会(SEC)公开披露招股书，其早于2021年6月17日在SEC秘密递表，股票代码RPET，拟在美国纳斯达克IPO上市。

新瑞鹏招股书链接：

https://www.sec.gov/Archives/edgar/data/1841931/000119312523013126/d148072df1.htm

主要业务

新瑞鹏，作为一家全国性的宠物医院连锁运营商，公司在宠物护理行业经营逾20年，是中国历史最悠久的全国性宠物医院连锁运营商。

根据弗若斯特沙利文的数据，按2020年和2021年的医院数量和宠物护理服务收入来看，新瑞鹏是中国最大的宠物护理平台、全球第二大宠物护理平台。截至2022年9月30日，公司拥有23个宠物医院品牌、1942家宠物医院，公司在31个省份、114个城市开展业务。2021年公司在中国一线城市的宠物护理市场份额约为30%。

新瑞鹏，以宠物护理服务(主要包括宠物医疗服务及美容服务)、供应链服务(主要包括宠物食品的销售、药品、医疗器械和材料等宠物用品,提供给第三方宠物医院、宠物诊所和宠物店)和本地服务(主要包括通过公司自己和第三方的在线平台和线下渠道向个人客户销售宠物产品)为三大支柱，并已扩展到其他业务领域(包括第三方诊断、继续兽医教育和营销即服务)。根据弗若斯特沙利文的资料，公司因此成为中国领先的宠物医院数量、收入及服务范围的一站式宠物护理平台，为宠物及宠物家长提供综合服务。自成立以来，公司构建了覆盖宠物全生命周期的数字化宠物护理平台，本着让宠物更健康，提供优质宠物护理服务的初衷。通过多年积累的运营经验，公司通过有机增长和收购相结合，实现了宠物护理服务、供应链服务和本地服务的快速网络扩张。

股东架构

招股书显示，新瑞鹏的股东架构如下：

彭永鹤 Yonghe Peng，通过Vet Leap Eternity直接持有2.53762948亿股、占股权的1.87%；

张延忠 Yanzhong Zhang，通过RP Passion Enterprise Management Company直接持有1.01817950亿股、占股权的0.75%；

某些董事、管理人员和其他为公司发展做出贡献的个人的利益而持有公司的股份

RP Chen Rui Enterprise Management Company持有7.58843690亿股、占股权的5.59%；

RP Rui You Enterprise Management Company持有6.35770514亿股、占股权的4.69%；

RP Ye Bei Enterprise Management Company持有4.65452291亿股、占股权的3.43%；

RP Sheng Peng Enterprise Management Company持有0.56527566亿股、占股权的0.42%；

RP Peng Cheng Enterprise Management Company持有0.78563129亿股、占股权的0.58%；

Vet Time Enterprise Management Company持有0.71812270亿股、占股权的0.53%；

公司在中国收购的一些宠物医院的前股东所持有的股份

RP Pulse Holdings持有5.41069195亿股、占股权的3.99%；

Vet Harvest Enterprise Management Company持有5.02174623亿股、占股权的3.70%；

Vet Cloudpet Intermediate持有1.21296465亿股、占股权的0.89%；

Vet Aino Family持有0.60562750亿股、占股权的0.45%；

Puppytown Holdings持有0.14086089亿股、占股权的0.10%；

Aino Brothers Holding持有0.08260246亿股、占股权的0.06%；

RP Passion Enterprise Management Company持有6.41732415亿股、占股权的4.73%；

彭永鹤 Yonghe Peng，通过Vet Leap Eternity、以及通过Entities affiliated with Yonghe Peng控制上述公司，合计控制43.11732141亿股、占股权的31.79%；

张延忠Yanzhong Zhang，通过RP Passion Enterprise Management Company以及上述中的部分公司，合计持有2.2%的股权；

刘朗 Lang Liu，持有不到1%的股权；

王烈胜 Liesheng Wang，持有不到1%的股权；

肖冰 Bing Xiao，持有不到1%的股权；

高瓴资本，通过Hillhouse Entities持有控制48.60984913亿股、占股权的35.84%。

公司架构

招股书显示，新瑞鹏的架构如下：

管理层

招股书显示，新瑞鹏的管理层如下：

彭永鹤 Yonghe Peng

Yonghe Peng has served as our director since the inception of our company, co-chairman of our board of directors since December 2019 and our president since June 2019. Mr. Peng founded Ruipeng Pet Hospital in December 1998 and has served as the chairman of the board of directors since November 2013 and president of Ruipeng Pet Healthcare Group Co., Ltd. since February 2016. Mr. Peng also served as the general manager of Shenzhen Sunsmile Biotechnology Co., Ltd. from May 2005 to October 2011. From September 1997 to November 1998, Mr. Peng worked as a veterinarian at the Institute of Pest Control in Guangdong Shenzhen Animal and Plant Inspection and Quarantine Bureau. From December 1994 to August 1997, Mr. Peng worked as a lecturer at Qinghai Vocational and Technical Institute of Animal Husbandry and Veterinary. From September 1991 to November 1994, Mr. Peng worked as a veterinarian at Xining Diary Farm of Qinghai Province in China. Mr. Peng received his bachelor’s degree in veterinary medicine from Qinghai University in 1991.

李良 Liang Li

Liang Li has served as our director and co-chairman of our board of directors since March 2020. Mr. Li has served as a partner at Hillhouse Investment since November 2005. From March 2001 to November 2005, Mr. Li worked as the general manager at State Research Internet and Data (Beijing) Co., Ltd. From July 1997 to March 2001, Mr. Li worked as the vice-general manager at State Research Information and Technology Co., Ltd. Mr. Li received his bachelor’s degree in automation in 1994 and his master’s degree in systems engineering in 1997 from Tsinghua University.

刘朗 Lang Liu

Lang Liu has served as our director since the inception of our company. Dr. Liu joined our group in December 2016. From 2006 to 2016, Dr. Liu served as the chairman of the board of directors at Beijing Community and Asset Management Co., Ltd. Dr. Liu received his bachelor’s, master’s and doctoral degrees in veterinary medicine from China Agricultural University in 1986, 2004 and 2009, respectively.

张延忠 Yanzhong Zhang

Yanzhong Zhang has served as our director since the inception of our company. Mr. Zhang joined our group in 2002 and has held several positions, including a veterinarian of Ruipeng Pet Hospital, and the director, general manager and the vice president of Ruipeng Pet Healthcare Group Co., Ltd. From July 2001 to February 2002, Mr. Zhang worked as a veterinarian at Fujian Changfu Group. Mr. Zhang graduated from Fujian Agriculture and Forestry University in 2001 and received his master’s degree in veterinary medicine from South China Agricultural University in 2010.

王烈胜 Liesheng Wang

Liesheng Wang has served as our director since the inception of our company. Mr. Wang joined our group in April 2010 and has held several positions, including the director of human resources department at Ruipeng Pet Hospital and the vice president and director of the board of Ruipeng Pet Healthcare Group Co., Ltd. Prior to joining us, Mr. Wang worked as the human resources director at Shenzhen Minhua Furniture Manufacturing Co., Ltd. from September 2008 to April 2010. From July 2007 to July 2008, Mr. Wang worked as the human resources manager at Shenzhen Yekalon Hardware Development Co., Ltd. From May 2004 to June 2007, Mr. Wang worked as the head of human resources department at Huawei Technologies Co., Ltd. From July 2003 to May 2004, Mr. Wang worked at human resources department at Foxconn Technology Group. Mr. Wang received his bachelor’s degree in human resources management from Guizhou University in 2003.

于铁铭 Tieming Yu

Tieming Yu has served as our director since March 2021. Mr. Yu currently serves as a Partner of Hillhouse Investment. Prior to joining Hillhouse Investment in February 2016, Mr. Yu worked as a senior associate at Keytone Ventures from May 2014 to February 2016. Prior to that, Mr. Yu worked as manager of capital market and accounting consulting service group at PricewaterhouseCoopers from October 2011 to May 2014 and as the manager of its global capital market group from August 2006 to October 2011. Mr. Yu received both his bachelor’s degree in management in 2003 and his master’s degree in accounting in 2006 from Beijing Jiaotong University.

魏山巍 Shanwei Wei

Shanwei Wei has served as our director since July 2022. Mr. Wei has been a managing director of Hillhouse Investment since April 2021. Prior to that, Mr. Wei worked as the co-head of the investment banking department of China Renaissance and the chief executive officer of Huaxing Securities (formerly known as Huajing Securities) from April 2015 to March 2021. From December 2012 to March 2015, Mr. Wei was the chief executive officer and the chairman of the board of directors of China Pingan Securities (Hong Kong). From May 2010 to November 2012, he served as a vice president of the investment banking department of Credit Suisse Founder Securities Ltd. From July 2006 to April 2010, Mr. Wei was a vice president of the investment banking department of CITIC Securities Company Limited. Mr. Wei obtained his bachelor’s degree in finance in 2002, and his master’s degree in finance in 2006, both from Renmin University of China.

肖冰 Bing Xiao

Bing Xiao has served as our director since the inception of our company. Mr. Xiao has worked as the vice president and chief executive officer at Shenzhen Fortune Wisdom Venture Capital Co., Ltd. since December 2008. From December 2002 to April 2018, Mr. Xiao worked as the chief executive officer at Shenzhen Fortune Venture Capital Co., Ltd. Mr. Xiao received his bachelor’s degree in economics from Renmin University of China in 1990 and his master’s degree in economics from Jinan University in 1995.

石晟昊 Shenghao Shi

Shenghao Shi has served as our director since November 2021. Mr. Shi has over 30 years’ experience in operation, investment and management, mostly in the healthcare industry. Mr. Shi currently serves as a managing director of Riverhead Capital, a private equity investment fund. Prior to joining Riverhead Capital in January 2020, Mr. Shi worked as a managing director of Sinopharm Capital Investment Management Co., Ltd. from July 2015 to December 2019. Prior to that, Mr. Shi worked as the general manager of the greater China region of Dentsply Group from September 2013 to June 2015. From July 2011 to September 2013, Mr. Shi worked as a vice president at Wego Group. From January 2008 to July 2011, Mr. Shi worked as the general manager of the greater China region of Bayer Group. From August 2006 to January 2008, Mr. Shi worked as the regional manager of Taiwan and Hong Kong at Bard Medical. Mr. Shi received his bachelor’s degree in English from Capital Normal University in 1990, and his EMBA from China Europe International Business School in 2005.

周晨光 Chenguang Zhou

Chenguang Zhou has served as our chief financial officer since the inception of our company. Prior to joining us in May 2019, Mr. Zhou worked at China National Cereals, Oils and Foodstuffs Corporation from late 2006 to 2019, holding several positions, including chief financial officer at China Foods Limited from 2015 to 2018, director at China Foods Limited from 2017 to 2018, and general manager of audit department at COFCO Meat Investment Co., Ltd. from 2011 to 2015. Prior to that, Mr. Zhou worked as the Deputy Finance Director at American International Assurance Co., Ltd. in late 2006, and as the Finance Manager at Lafarge Shui On Cement Limited from 2004 to early 2006. Mr. Zhou received his bachelor’s degree in accounting from Northeastern University of Finance and Economics in 1999 and his master’s degree in management from University of Waikato in 2002. Mr. Zhou is a Certified Internal Auditor and a certified member of the Institute of Financial Accountants at FFA level and Australia Institute of Public Accountants. Mr. Zhou also obtained the Certification in Risk Management Assurance.

公司业绩

招股书显示，在过去的2020年、2021年和2022年前九个月，新瑞鹏的收入分别为30.08亿、47.84亿和43.15亿元人民币，相应的净亏损分别为11.60亿、13.72亿和7.56亿元人民币。